SPAC22G7.03 Antibody

What is SPAC22G7.03 and what organism does it originate from?

SPAC22G7.03 refers to an uncharacterized protein from Schizosaccharomyces pombe (strain 972/24843), commonly known as fission yeast. This protein is referenced in scientific databases with the UniProt Primary Accession number Q09797 . Fission yeast serves as an excellent model organism for studying eukaryotic cell biology, with SPAC22G7.03 representing one of many proteins being investigated to better understand cellular functions conserved across species.

The protein is sometimes referred to by synonym "Uncharacterized protein C22G7.03" in scientific literature and product descriptions. Researchers studying this protein typically utilize antibodies specifically developed against this target to elucidate its expression, localization, and potential functions within cellular processes.

What applications has the SPAC22G7.03 antibody been validated for?

Based on available product information, the SPAC22G7.03 antibody has been tested and validated for ELISA (Enzyme-Linked Immunosorbent Assay) and Western Blot applications . These techniques allow researchers to detect and quantify the protein in various experimental contexts.

Western blotting represents a particularly valuable application for determining protein expression levels under different experimental conditions or across various genetic backgrounds. For proper identification of the antigen, researchers should establish appropriate controls including positive controls (wild-type yeast) and negative controls (deletion mutants) when possible.

What are the optimal growth conditions for S. pombe when preparing samples for SPAC22G7.03 detection?

For physiological experiments involving SPAC22G7.03 antibodies, it is critical to maintain cultures in mid-exponential growth between 2 x 10^6 and 1 x 10^7 cells/ml. The optical density (OD) of a culture can be used to measure cell concentration, where OD595 = 0.1 represents approximately 2 x 10^6 cells/ml . This relationship remains linear up to about OD 1.0.

For optimal growth, cultures should be maintained at temperatures below 30°C, as higher temperatures can adversely affect cellular functions and protein expression. When preparing samples for antibody-based detection techniques, it's important to note that cells in stationary phase typically accumulate in G1 or G2 phase depending on nutrient limitations, which may affect expression levels of certain proteins . Therefore, standardizing the growth phase is essential for reproducible results.

How can I validate the specificity of the SPAC22G7.03 antibody in my experimental system?

Validating antibody specificity is crucial for reliable experimental outcomes. Implement a multi-faceted approach including:

• Genetic Controls: Compare signal between wild-type and SPAC22G7.03 deletion strains (if available). Absence of signal in knockout cells strongly supports antibody specificity.

• Peptide Competition Assay: Pre-incubate the antibody with excess purified SPAC22G7.03 peptide/protein before application to samples. Signal reduction indicates specific binding.

• Cross-Reactivity Assessment: Test the antibody against closely related proteins or in heterologous systems to determine potential off-target binding.

• Multiple Detection Methods: Validate findings using complementary techniques (e.g., if detected by Western blot, confirm with immunofluorescence).

This comprehensive validation approach mirrors methodologies established for other antibodies used in model organism research, such as those documented for pneumococcal capsular polysaccharide antibodies , where careful epitope specificity testing was critical for determining antibody efficacy.

What experimental design considerations should be implemented when using SPAC22G7.03 antibody for co-immunoprecipitation studies?

When designing co-immunoprecipitation (Co-IP) experiments to investigate SPAC22G7.03 protein interactions, consider the following critical factors:

• Cell Lysis Optimization: Use gentle lysis conditions (e.g., 1% NP-40 or 0.5% Triton X-100) to preserve protein-protein interactions. Avoid harsh detergents like SDS that can disrupt native complexes.

• Buffer Composition: Include stabilizing agents (5-10% glycerol, 1 mM DTT) and appropriate salt concentration (typically 100-150 mM NaCl) to maintain physiological interactions while minimizing non-specific binding.

• Antibody Coupling Strategy: For consistent results, covalently couple the SPAC22G7.03 antibody to sepharose or magnetic beads using optimized crosslinking protocols to prevent antibody leaching during elution.

• Controls Implementation: Include critical controls such as:

  • IgG control precipitation with the same host species as the SPAC22G7.03 antibody

  • Input sample (5-10% of lysate used for IP)

  • Precipitations from cells lacking the target protein

• Elution Method Selection: Choose between native elution (competing peptide) or denaturing conditions (SDS buffer) based on downstream applications and the stability of the interactions being studied.

This approach parallels strategies employed in antibody studies for complex formation analysis, similar to those used in investigating therapeutic antibody cocktails against SARS-CoV-2, where understanding protein-protein interactions was vital for determining synergistic neutralization mechanisms .

How can I reduce background signal when using SPAC22G7.03 antibody in immunofluorescence microscopy?

High background in immunofluorescence experiments with fission yeast can significantly impact data quality. Address this challenge through a systematic optimization approach:

• Fixation Protocol Refinement: Test both formaldehyde (3.7% for 30 minutes) and methanol (100% at -20°C for 8-10 minutes) fixation methods to determine which preserves epitope accessibility while minimizing autofluorescence.

• Blocking Enhancement: Extend blocking to 60-90 minutes using 5% BSA or 5% normal serum from the same species as the secondary antibody host. Adding 0.1% Triton X-100 to the blocking solution can improve penetration.

• Antibody Dilution Optimization: Test serial dilutions of SPAC22G7.03 antibody (starting with 1:200, 1:500, 1:1000) to identify the minimal concentration that produces specific signal.

• Secondary Antibody Selection: Use highly cross-adsorbed secondary antibodies specific to rabbit IgG to minimize cross-reactivity with yeast proteins. Starting dilution of 1:1000 is recommended.

• Washing Protocol Intensification: Implement stringent washing (4-5 times, 10 minutes each) with PBS containing 0.1% Tween-20 after both primary and secondary antibody incubations.

When documenting results, capture images of negative controls (secondary antibody only, and primary antibody on knockout strains if available) using identical exposure settings to demonstrate specific labeling.

What strategies can improve protein extraction efficiency for detecting SPAC22G7.03 in S. pombe?

Efficient protein extraction from fission yeast represents a critical first step for successful detection of SPAC22G7.03. Implement these refined extraction protocols:

• Growth Phase Standardization: Harvest cells in mid-exponential phase (OD595 = 0.5-0.8) for most consistent protein expression and extraction efficiency .

• Cell Wall Disruption Method: Optimize mechanical disruption through glass bead beating in cold conditions (5 cycles of 30 seconds beating followed by 30 seconds on ice). For scaled-up preparations, consider using a French press or high-pressure homogenizer.

• Lysis Buffer Composition: Use a buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.1% NP-40, 1 mM DTT, and protease inhibitor cocktail. If protein phosphorylation status is relevant, add phosphatase inhibitors (10 mM NaF, 1 mM Na3VO4).

• Extraction Temperature Control: Maintain samples at 4°C throughout the extraction process to minimize protein degradation and preserve post-translational modifications.

• Sample Clarification: Centrifuge lysates at 15,000×g for 15 minutes at 4°C, then collect and quantify the supernatant using Bradford or BCA protein assay before proceeding to immunological detection.

This methodology incorporates principles from successful protein extraction protocols documented for antibody research in various model systems .

What are best practices for quantifying SPAC22G7.03 expression across different experimental conditions?

Accurate quantification of SPAC22G7.03 requires rigorous methodology and appropriate controls:

• Signal Normalization Strategy: When analyzing Western blot data, normalize SPAC22G7.03 signal to both:

  • A housekeeping protein control (e.g., actin or tubulin)

  • Total protein stain (Ponceau S or Coomassie)

• Technical Replication: Perform at least three independent biological replicates with technical duplicates to establish statistical significance.

• Dynamic Range Determination: Generate a standard curve using recombinant protein or serially diluted positive control samples to ensure quantification occurs within the linear range of detection.

• Statistical Analysis Implementation: Apply appropriate statistical tests (t-test for two conditions, ANOVA for multiple conditions) with post-hoc tests when comparing expression across different experimental groups.

• Presentation Standards: Report results as fold change relative to control conditions with error bars representing standard deviation or standard error of the mean.

Table 1: Recommended Quantification Parameters for SPAC22G7.03 Expression Analysis

This quantification framework builds on established principles for antibody-based detection systems used in research contexts similar to those for CD275 monoclonal antibody analysis .

How should subcellular localization data for SPAC22G7.03 be interpreted in relation to cell cycle phases?

Interpreting subcellular localization of SPAC22G7.03 throughout the cell cycle requires careful correlation with cell cycle markers:

• Cell Cycle Stage Identification: In fission yeast, cell cycle stage can be determined by:

  • Cell length (increases through interphase)

  • Nuclear morphology (via DAPI staining)

  • Septation index (presence and position of the division septum)

• Quantitative Localization Analysis: For each identified cell cycle stage:

  • Measure signal intensity across defined cellular compartments

  • Calculate nuclear-to-cytoplasmic ratio

  • Document any changes in punctate structures

• Co-localization Studies: Perform double-labeling with established markers for specific compartments (e.g., nuclear envelope, endoplasmic reticulum, Golgi, mitochondria) to precisely define SPAC22G7.03 localization.

• Dynamic Behavior Documentation: When possible, use live-cell imaging with SPAC22G7.03-GFP fusion proteins to track dynamic changes during cell cycle progression, validating observations with fixed-cell antibody staining.

• Functional Correlation: Correlate localization changes with known cell cycle events and protein function to develop mechanistic hypotheses.

For synchronized populations, techniques such as lactose gradient centrifugation or hydroxyurea block-and-release can provide enriched populations at specific cell cycle stages, allowing for more detailed analysis of SPAC22G7.03 behavior across the cell cycle .

How can I design structure-function studies using SPAC22G7.03 antibody?

Structure-function analysis of SPAC22G7.03 can be approached through a methodical experimental design:

• Domain-Specific Antibody Utilization: If epitope information is available for the SPAC22G7.03 antibody, use it to probe specific protein domains in wild-type and mutant contexts.

• Mutant Variant Analysis: Generate a series of deletion or point mutation constructs targeting predicted functional domains of SPAC22G7.03, then use the antibody to assess expression, stability, and localization changes.

• Protein Interaction Mapping: Combine immunoprecipitation with mass spectrometry to identify interaction partners, then systematically disrupt predicted interaction domains to determine functional consequences.

• Post-translational Modification Detection: Use the antibody in combination with specific treatments (phosphatase treatment, deglycosylation) to identify modifications that may regulate SPAC22G7.03 function.

• Comparative Analysis Across Conditions: Examine SPAC22G7.03 behavior under various stresses or cell cycle stages to identify condition-dependent functional changes.

This approach follows established principles for structure-function analysis similar to those employed in antibody efficacy studies against Streptococcus pneumoniae, where relationships between antibody structure, specificity, and efficacy were systematically investigated .

What complementary techniques should be used alongside SPAC22G7.03 antibody detection for comprehensive functional analysis?

A comprehensive functional analysis of SPAC22G7.03 requires integration of multiple experimental approaches:

• Genetic Manipulation: Generate knockout, knockdown, and overexpression strains to assess phenotypic consequences of altered SPAC22G7.03 levels. Use antibody detection to confirm expression changes.

• Transcriptomic Profiling: Perform RNA-seq or microarray analysis comparing wild-type and SPAC22G7.03 mutant strains to identify downstream genes affected by SPAC22G7.03 perturbation.

• Protein-Protein Interaction Network: Combine antibody-based co-immunoprecipitation with proximity labeling techniques (BioID, APEX) to construct a comprehensive interactome.

• Cell Biology Assays: Correlate antibody-detected expression/localization with functional assays examining processes such as cell cycle progression, stress response, and organelle dynamics.

• Phenotypic Rescue Experiments: Use the antibody to verify expression of wild-type or mutant SPAC22G7.03 in complementation studies to determine which protein domains are necessary and sufficient for function.

This multi-method approach parallels comprehensive antibody cocktail development strategies where cooperativity between different detection methods revealed synergistic mechanisms that would not have been evident using single analytical approaches .